DOP01: Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paperECCO'24 Stockholm 2024
DOP02: Developing explicit thresholds for outcomes to inform (GRADE) Evidence to Decision frameworks for Inflammatory Bowel Disease guidelines.ECCO'24 Stockholm 2024
DOP03: Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey on processes and outcomesECCO'24 Stockholm 2024
DOP04: Screening and management of fistula cancers in patients with perianal fistulising Crohn’s Disease: an expert consensusECCO'24 Stockholm 2024
DOP05: Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s Disease.ECCO'24 Stockholm 2024
DOP06: Development of simplified scoring system to predict two-year clinical remission of patients with Ulcerative Colitis after treatment with vedolizumabECCO'24 Stockholm 2024
DOP07: Monitoring disease activity by intestinal ultrasound predicts biologic treatment persistence in patients with Inflammatory Bowel DiseaseECCO'24 Stockholm 2024
DOP08: A novel multiomic approach to unravel the mechanisms of action of biologics and tofacitinib in Inflammatory Bowel Disease.ECCO'24 Stockholm 2024
DOP09: Models for predicting Crohn Disease (CD) exacerbation using serum and fecal metabolomicsECCO'24 Stockholm 2024
DOP10: Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE TrialECCO'24 Stockholm 2024
DOP11: Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trialECCO'24 Stockholm 2024
DOP12: Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trialECCO'24 Stockholm 2024
DOP14: Proctocolectomy is associated with improved transplant-free survival in patients with primary sclerosing cholangitis: results from a pooled collaborative international studyECCO'24 Stockholm 2024
DOP16: Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extensionECCO'24 Stockholm 2024
DOP17: Tofacitinib versus Vedolizumab Among Bio-naïve Patients With Ulcerative Colitis: A Real-World Propensity-Weighted ComparisonECCO'24 Stockholm 2024
DOP18: Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trialECCO'24 Stockholm 2024